Implementing Effective Acute and Transitional Care Strategies for Hepatic Encephalopathy

Release date: August 23, 2019
Expiration date: August 23, 2020
Estimated time to complete activity: 60 minutes

 

 

FACULTY

Arun B. Jesudian, MD, FACG
Assistant Professor of Medicine
Joan and Sanford I. Weill
Department of Medicine
Director Inpatient Liver Services
Weill Cornell Medical College
New York, New York

PROGRAM OVERVIEW

HE is a commonly occurring complication of liver disease with the potential to cause severe impairments in brain function and substantially diminished overall quality of life. In the absence of appropriate treatment, it is associated with poor survival and a high risk of recurrence and hospitalization. Although treatment of patients presenting with acute overt HE appears to be generally aligned with expert recommendations, there remains a significant need for earlier disease intervention, as well as secondary prophylaxis following an overt HE episode.

TARGET AUDIENCE

This educational initiative has been designed for physicians, hospital-based specialists, nurse practitioners, physician assistants, nurses, and case managers involved in the care of patients with HE.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

  • Identify symptoms and risk factors of HE and approaches to diagnosis that are concordant with current guidelines recommendations
  • Utilize available clinical and observational data to design effective acute and prophylactic treatment regimens for patients with HE
  • Implement transitional and long-term care strategies to reduce rehospitalization in patients with HE
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of August 23, 2019 through August 23, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Arun B. Jesudian, MD, FACG
Consulting Fees: Valeant Pharmaceuticals North America LLC
Speakers’ Bureaus: Valeant Pharmaceuticals North America LLC

The Integrity CE planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Salix Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from Salix Pharmaceuticals, Inc.

Continue to Pretest